Head office: +98 21 8854 0521 Saturday to Wednesday, 8:00–17:00 info@meshcutpharmed.com Contact usPartnership
Meshkat Pharmed DistributionMeshkat Pharmed DistributionNationwide distribution of medicines and health products

Navepegritide: first approval

Navepegritide is a C-type natriuretic peptide (CNP) prodrug developed by Ascendis Pharma for the treatment of achondroplasia and under investigation for hypochondroplasia. Given once…

ArticleOctober 20, 2026
Navepegritide: first approval

Navepegritide is a C-type natriuretic peptide (CNP) prodrug developed by Ascendis Pharma for the treatment of achondroplasia and under investigation for hypochondroplasia. Given once weekly, navepegritide is designed to provide sustained release of, and continuous exposure to, active CNP — which is needed to counter overactive fibroblast growth factor receptor 3 signaling in achondroplasia — leading to improved growth velocity. Navepegritide recently received accelerated approval in the United States to increase linear growth in pediatric patients aged 2 years and older with achondroplasia and open epiphyses. This article summarizes the milestones in the development of navepegritide leading to this first approval for achondroplasia.

Read more: PMC

This article is for educational and informational purposes only and is not a substitute for advice, diagnosis or treatment by a physician or pharmacist.

Original Persian text: meshcutpharmed.com